SpecialtiesCarol M. Richman, M.D. 
Clinical/Research Interests
Title:
Specialty:
Center/Program Affiliation:
Address:
4501 X St.
Sacramento, CA 95817
Phone:
Education:
Bronx, New York
M.D. 1971
Washington University
St. Louis, Missouri
B.A. 1967
Internships:
Cambridge, Massachusetts
1971-72
Residency:
Boston, Massachusetts
1972-73
Internal Medicine
Fellowships:
Boston, Massachusetts
1973-75
Hematology/Oncology
Board Certifications:
Professional Memberships:
American Society of Clinical Oncology
American Society of Hematology
Southwest Oncology Group - Bone Marrow Transplant Committee
Honors and Awards:
Alpha Omega Alpha, 1971
Phi Beta Kappa, 1967
Select Recent Publications:
Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1192-8. Epub 2006 Sep 11.
Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med. 2005 Jun;46(6):1034-41.
DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s.
Richman CM, SJ DeNardo, RT O’Donnell, A Yuan, DS Goldstein, S Shen, JM Tuscano, T Wun, HK Chew, PN Lara, DL Kukis, A Natarajan, CG Meares, KR Lamborn, GL DeNardo. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent HAMA. Clinical Cancer Research, 2005 Aug 15;11(16):5920-5927.
Miers L, K Lamborn, A Yuan, C Richman, A Natarajan, S DeNardo, G DeNardo. Does paclitaxel given after 111In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? Clin Cancer Res. 2005 Oct 1;11(19 Suppl):7158s-7163s.
Rubin D, T Albertson, C Richman. Intensive care unit admissions in patients with hematologic malignancies: Outcomes and prognostic indicators. Abstract presented at the 47th Annual Meeting of the American Society of Hematology. Blood, 106(11):Abstract # 752.
Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C. Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. Am J Hematol. 2004 Apr;75(4):231-8.
DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm. 2003 Apr;18(2):231-7.
DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 1;9(10 Pt ):3938S-44S.
Hutchinson K, KM Kopko, KN Muto, JM Tuscano, RT O'Donnell, PB Holland, CM Richman, TG Paglieroni, T Wun. Early diagnosis and successful treatment of transfusion-associated graft-versus-host disease with autologous peripheral stem cell transplantation. Transfusion, 2002 Dec;42:1567-1572.
